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is hishLy variable; however, chorioretina[ invoLve- 
ment has been rarely described. The case: An 
8 year-oLd girt received a cord blood transpLanta- 
tion in February 2005 for a relapsing acute [ym- 
phobtastic [eukaemia. She was treated by ganci- 
c[ovir for o./tornegalovirus (CMV) reactivation from 
April to June 2005. Six months after BMT, she 
presented with prolonged fever, tonsittar necrosis, 
smaLL pulmonary nodules and positive EBV-PCR in 
blood and CSF. She underwent biLateraL tonsiLLec- 
tomy that showed poLymorphic PTLD induced by 
EBV. She was treated with monocLona[ anti-CD20 
antibody infusions and a reduction in immunosup- 
pression. ConsequentLy, she improved and EBV-PCR 
became negative. Seven months after BMT, the 
fever recurred, associated with enlarging cervical 
adenopathies nlargement, pulmonary nodules and 
positive PCR for CMV and EBV in blood. PathoLogicaL 
analysis of pulmonary nodules and cervical Lymph 
nodes biopsies confirmed PTLD. One month Later, 
the patient complained of sudden toss of decreased 
vision in her Left eye. The ophthaLmoLogic exami- 
nation showed a chorioretinitis and acute retinal 
necrosis (ARN). EBV PCR of vitreous materiel re- 
vealed high viral toad although it was negative 
in blood. The pathoLogicaL analysis of the retinal 
biopsy showed an important infiltration by [ym- 
phoproLiferatives ceLLs LMP-1 positive, but negative 
for CD20. In situ hybridization with Eber probe 
confirmed the presence of EBV. Specific treatment 
consisted of Local radiation therapy (150Gy). Five 
months after, visual acuity was 6/6 in the right eye 
and perception of hand movement at 1 meter in 
the Left eye. 
Discussion: We report a rare event of confirmed 
chorioretina[ PTLD induced by EBV after BMT in a 
child. ALthough rare, ocular PTLD should be part 
of the differential diagnosis of chorioretinitis and 
ARN in these patients. Diagnosis was confirmed 
by retinal biopsies. Positive EBV-PCR on vitreous 
fluid pleads in favour of the diagnosis and can be 
helpfuL, since there is not always a good correLa- 
tion between viral Loads in the blood and those in 
aqueous and vitreous humor. 
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Background: Invasive funsal infection (IFI) is an 
important cause of morbidity and mortality for 
hematopoietic stem ceLL transplant (HSCT) recip- 
ients with graft-versus-host disease (GVHD). Ef- 
ficacy and safety of prophylaxis with posacona- 
zoLe (POS) and fluconazoLe (FLU) were evaluated 
in HSCT recipients with GVHD in an internationaL, 
randomized, cLinicaL triaL. 
Objectives: This subanaLysis evaluated IFI develop- 
ment and associated mortality. 
Methods: Patients were randomized to receive 
POS oral suspension (200rag 3× daily) or FLU 
encapsulated tablets (400rag 1× daily) for up 
to 112 days. Primary endpoint was incidence of 
proven/probabLe IFI, determined by blinded expert 
paneL, during the primary time period (randomiza- 
tion to day 112). Incidence of proven/probabLe IFI 
was also assessed during the on-treatment phase 
(from first to Last dose plus 7 days). Deaths during 
the study were included in a mortality analysis. 
Investigators determined cause of death. 
Results: 600 patients were randomized to receive 
POS (n=301) or FLU (n=299). During the primary 
time period, prophylaxis with POS resulted in fewer 
IFIs than with FLU (5% vs 9%, P=0.07) and sig- 
nificantly fewer cases of aspersillosis (2% vs 7%, 
P =0.006). During the on-treatment phase, signifi- 
cantly fewer IFIs and cases of aspersillosis deveL- 
oped in the POS than the FLU group (2% vs 8%, 
P = 0.004; 1% vs 6%, P = 0.001, respectively). During 
the primary time period, of 16 patients in the POS 
group in whom IFI developed, 10 (63%) died; of 
27 patients in the FLU group, 18 (67%) died (tabLe). 
Among patients in whom IFI did not develop during 
the primary time period, 66/285 (23%) in the POS 
group and 66/272 (24%) in the FLU group died. 
Conclusions: In this study of HSCT recipients with 
GVHD, prophylaxis with POS resulted in fewer IFIs 
than did prophylaxis with FLU. MortaLity rates were 
higher among patients in either treatment group 
who had IFIs than those who did not. Data suggest 
early intervention such as prophylaxis with POS, 
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which significantly reduces the incidence of break- 
through IFI, may more be effective than treatment 
of established IFIs. 
Patients with IFIs POS (n = 16) FLU (n = 27) 
Total deaths, n (%) 10 (63) 18 (67) 
Cause of death, n (%) 
Progression of IFI 2 (13) 6 (22) 
HSCT/GVHD 2 (13) 6 (22) 
Adverse events 6 a (38) 5 b (19) 
Unknown 0 1 (4) 
alnc[udes: intracrania[ hemorrhage, brain stem herniation, bac- 
teria[ sepsis, cardiopu[monary arrest, disseminated varicella 
zoster, upper ~astrointestina[ b[eed. 
blnc[udes: diffuse a[veo[ar hemorrhage, cardiac and respiratory 
fai[ure, cytornesalovirus pneumonia, respiratory insufficiency. 
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Background: Risk factors for adenovirus (ADV) in- 
fection following a[[ogeneic stem ceil transplan- 
tation (ASCT) from retrospective studies include 
graft versus host disease (GVHD), T-ceil depleted 
grafts, [ymphopenia, retransp[antation, total body 
irradiation, use of multiple immunosuppressives, 
and mismatched or unrelated donors. 
Objectives: To perform a case-control study to 
ascertain risk factors for ADV infection in pediatric 
ASCT patients (pts). 
Methods: We prospectively studied 40 children 
from 9/8/03 to 12/1/05 for ADV infection for up 
to 1 year (y) following ASCT. The week prior to 
ASCT, a throat swab, urine, and stool were sent for 
viral culture, and plasma was sent for ADV PCR. The 
same specimens were obtained weekly for the first 
100 days (d), then monthly until 1 y after ASCT. We 
defined ADV infection as: (1) a positive ADV PCR, 
(2) >2 positive ADV cultures from separate sites, or 
(3) 1 positive culture plus clinical evidence of ADV. 
1 ADV infected pt was matched with 2 non-infected 
pts for gender and survival to at [east 21 d after the 
index case developed ADV. Risk factors were then 
compared. 
Results: 6 (15%) of the 40 ASCT pts developed 
ADV infection. Median age of case pts was 1.4y, 
while that of control pts was 9.3y. 2 of 6 
case pts received anti-thymocyte globulin (ATG) 
post-transplant as opposed to 0 of 2 matched 
controls. 2 of 6 case pts underwent previous ASCT 
compared with 1 of 12 controls. Case pts recovered 
their lymphocyte counts to 200/ram 3 a median of 
18.5 d following transplant while control pts were 
14 d. Matched related transplants occurred in only 
1 of 6 case pts but in 6 of 12 control pts. There 
were no differences between case and control pts 
regarding ethnicity, diagnosis leading to transplant, 
pretreatment conditioning, episodes of GVHD, or 
treatment with gancic[ovir. 
Conclusions: Younger age, receipt of ATG post- 
transplant, and a longer time to lymphocyte re- 
covery appeared to be risk factors for developing 
ADV infection. GVHD, total body irradiation, and 
conditioning regimen were not. Receipt of a trans- 
plant from a completely matched related donor 
appeared protective. 
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Background: CMV remains an important factor for 
outcome of a[[ogeneic stem ceil transplantation 
(SCT). The serological status of both donors and 
recipients are important factors for transplant out- 
come. 
Objective: Our aim was use the registry of the Eu- 
ropean Group for Blood and Marrow Transplantation 
to study trends over time as we[[ as analyzing the 
effects of age, gender, and country on the donor 
and recipient CMV serostatus. 
Patients ~ Methods: 40,311 patients and 23,048 
donors were selected from the registry database. 
The patients were transplanted 1985-2004. Logis- 
tic regression models were constructed predicting 
seropositivity using as covariates year of SCT, age, 
gender, and country for both patients and donors 
separately. 
Results: Females had a higher likelihood to be 
seropositive than males both among patients 
(OR 1.22; 1.15-1.30; p<.001) and donors (OR 1.23; 
1.13-1.34; p<0.001). The risk to be seroposi- 
tive increased by age (patients OR 1.19/decade; 
1.17-1.21; p<0.001; donors OR 1.24/decade; 
1.22-1.27; p<0.001) but decreased by calendar 
year (patients OR 0.98/year, 0.97-0.99; p < 0.001; 
donors 0.98/year; 0.97-0.98; p=0.001). There 
were major differences between different coun- 
tries with the BENELUX countries having the lowest 
and Italy the highest probabilities to be seroposi- 
tive for both patients and donors. 
